A Novel Treatment Strategy Utilizing Panobinostat for High-Risk and Treatment-Refractory Hepatoblastoma
Patients with metastatic, treatment-refractory, and relapsed hepatoblastoma (HB) have survival rates of less than 50% due to limited treatment options. To develop new therapeutic strategies for these patients, our lab has developed a preclinical testing pipeline. Given that histone deacetylase (HDAC) inhibition has been proposed for HB, we hypothesized that we could find an effective combination treatment strategy utilizing HDAC inhibition.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Andres F. Espinoza, Roma H. Patel, Kalyani R. Patel, Andrew A. Badachhape, Richard Whitlock, Rohit K. Srivastava, Saiabhiroop R. Govindu, Ashley Duong, Abhishek Kona, Pavan Kureti, Bryan Armbruster, Dina Kats, Ramakrishnan R. Srinivasan, Lacey E. Dobrolec Tags: Research Article Source Type: research
More News: Gastroenterology | Hepatoblastoma